Thyroxine Therapy in Adult Resistance to Thyroid Hormone Alpha (RTHα): Clinical Efficacy, Safety, and Metabolic Insights

Highlight

• High-dose levothyroxine (L-T4) therapy safely raises thyroid hormone levels in adult RTHα patients without adverse clinical effects over three years.
• Patients report improved quality of life despite biochemical profiles showing supraphysiological free thyroxine (FT4), free triiodothyronine (FT3), and reverse T3 (rT3) levels with suppressed TSH.
• Metabolomic analyses reveal significant reductions in multiple lipid classes, with no changes in bone mineral density (BMD), indicating nuanced metabolic consequences of therapy.
• Introduction of liothyronine (L-T3) replacement raises concerns due to cardiac arrhythmia in one patient, emphasizing cautious titration and monitoring.

Study Background

Resistance to thyroid hormone alpha (RTHα) is a rare, inherited disorder characterized by impaired action of thyroid hormone mediated through the thyroid hormone receptor alpha isoform. Clinically, patients present with symptoms resembling hypothyroidism but paradoxically normal or near-normal thyroid function tests, including thyroid-stimulating hormone (TSH), complicating diagnosis and therapeutic monitoring. Mutations in the THRA gene impair receptor-mediated signaling, thereby attenuating tissue responsiveness despite sufficient circulating thyroid hormones. Currently, standard treatment guidelines are lacking, and therapeutic strategies primarily aim to bypass receptor resistance using exogenous thyroid hormone administration to normalize symptomatology and metabolic function. This study addresses an unmet clinical need by systematically evaluating the safety, efficacy, and metabolomic effects of high-dose levothyroxine (L-T4) in adult patients harboring the Ala263Val mutation in THRA, thereby providing critical translational insights into management of RTHα.

Study Design

This pilot open-label study enrolled four adult RTHα patients confirmed to carry the Ala263Val mutation. Intervention involved administration of levothyroxine at a dosage of 1.75 µg/kg body weight, with longitudinal follow-up spanning three years. Key endpoints included biochemical thyroid hormone profiles (FT4, FT3, rT3, TSH), clinical cardiovascular and bone health parameters, bone mineral density (BMD) assessed by densitometry, and quality of life (QoL) measurement using the validated ThyPro questionnaire. An exploratory metabolomic investigation was conducted to delineate systemic biochemical changes induced by high-dose therapy. Partial substitution of L-T4 with liothyronine (L-T3) was trialed in select cases to assess the potential for improved metabolic correction.

Key Findings

Administration of supraphysiological doses of L-T4 effectively elevated circulating FT4, FT3, and rT3 levels above normal reference ranges, concomitantly suppressing TSH, consistent with expected negative feedback. Despite these hormonal extremes, no severe adverse clinical events were reported over the study period. Heart rate exhibited a transient increase following treatment initiation, paralleled by temporary elevations in bone turnover markers and sex hormone-binding globulin (SHBG), suggesting metabolic activation without sustained harm. Notably, BMD measurements remained stable, indicating preserved skeletal integrity under therapy.

From a metabolomic perspective, analysis revealed significant reductions across several lipid classes, potentially reflecting enhanced lipid catabolism or altered lipid metabolism secondary to thyroid hormone excess. Although these changes may have beneficial implications, their long-term impact warrants further investigation.

Quality of life improved significantly in patients adherent to treatment regimens, underscoring the therapeutic benefit from a symptomatic and functional standpoint. However, the attempt to partially replace L-T4 with L-T3 resulted in one patient developing a brief non-sustained ventricular tachycardia episode, highlighting a safety concern and the necessity for careful cardiovascular monitoring when introducing L-T3.

Expert Commentary

The therapeutic management of RTHα presents fundamental challenges due to receptor-level resistance and the paradoxical disconnect between clinical phenotype and routine thyroid function tests. This study provides pivotal evidence supporting the tolerability and symptomatic benefit of high-dose L-T4 treatment in adult patients with this rare disorder, marking a step forward in personalized therapy. The metabolomic findings offer intriguing mechanistic insights into systemic effects beyond conventional thyroid hormone metrics, suggesting altered lipid metabolism as a component of treatment response.

Caution is advised when considering L-T3 supplementation given its potent biological effects and arrhythmogenic potential, especially in susceptible individuals. The small patient cohort and open-label design limit definitive conclusions; thus, larger controlled studies are needed to confirm efficacy, elucidate optimal dosing regimens, and investigate long-term safety profiles.

Furthermore, the preservation of bone density despite transient bone marker elevations is reassuring, though vigilance should continue given the known catabolic effects of thyroid hormones on bone tissue. Integration of comprehensive metabolomic analyses in future studies may uncover biomarkers predictive of treatment response or adverse effects, enhancing clinical decision-making.

Conclusion

High-dose levothyroxine therapy in adults with RTHα appears safe and efficacious in improving quality of life and biochemical thyroid status despite supraphysiological hormone concentrations. The metabolic footprint of treatment, highlighted by lipid alterations, suggests complex systemic effects that extend beyond traditional thyroid parameters. While partial L-T3 replacement holds theoretical benefit, it incurs a risk of cardiac arrhythmias necessitating prudence. This pilot study lays groundwork for future research aimed at refining therapeutic approaches in this rare but impactful thyroid hormone resistance syndrome.

Funding and ClinicalTrials.gov

The original study does not specify funding sources or ClinicalTrials.gov registration details. Future research efforts should prioritize transparency in funding and registration to enhance study credibility and reproducibility.

References

1. Westbye AB, Dahll LK, Bredahl MK, Thorsby PM, Hammerstad SS. Thyroxine Treatment of Adult RTHα Patients: Safety, Efficacy, and Metabolomic Changes. Thyroid. 2026 Jun 11;36(7):788-794. PMID: 42273878.
2. Refetoff S, Dumitrescu AM. Thyroid hormone resistance. In: Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2021.
3. Moran C, Chatterjee K. The genetics of thyroid hormone resistance syndromes. Mol Cell Endocrinol. 2015;418 Pt 1:6-12.
4. Minert AO, Schussler GC, Cooper DS. Therapy of thyroid hormone resistance syndromes. Best Pract Res Clin Endocrinol Metab. 2019;33(6):101285.